Title |
Chimeric antigen receptor T cells: a novel therapy for solid tumors
|
---|---|
Published in |
Journal of Hematology & Oncology, March 2017
|
DOI | 10.1186/s13045-017-0444-9 |
Pubmed ID | |
Authors |
Shengnan Yu, Anping Li, Qian Liu, Tengfei Li, Xun Yuan, Xinwei Han, Kongming Wu |
Abstract |
The chimeric antigen receptor T (CAR-T) cell therapy is a newly developed adoptive antitumor treatment. Theoretically, CAR-T cells can specifically localize and eliminate tumor cells by interacting with the tumor-associated antigens (TAAs) expressing on tumor cell surface. Current studies demonstrated that various TAAs could act as target antigens for CAR-T cells, for instance, the type III variant epidermal growth factor receptor (EGFRvIII) was considered as an ideal target for its aberrant expression on the cell surface of several tumor types. CAR-T cell therapy has achieved gratifying breakthrough in hematological malignancies and promising outcome in solid tumor as showed in various clinical trials. The third generation of CAR-T demonstrates increased antitumor cytotoxicity and persistence through modification of CAR structure. In this review, we summarized the preclinical and clinical progress of CAR-T cells targeting EGFR, human epidermal growth factor receptor 2 (HER2), and mesothelin (MSLN), as well as the challenges for CAR-T cell therapy. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Finland | 1 | <1% |
Unknown | 403 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 68 | 17% |
Student > Ph. D. Student | 58 | 14% |
Student > Master | 55 | 14% |
Researcher | 52 | 13% |
Other | 23 | 6% |
Other | 45 | 11% |
Unknown | 103 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 87 | 22% |
Medicine and Dentistry | 63 | 16% |
Immunology and Microbiology | 51 | 13% |
Agricultural and Biological Sciences | 31 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 28 | 7% |
Other | 35 | 9% |
Unknown | 109 | 27% |